In recent years, messenger RNA (mRNA) vaccines have shown significant success in preventing viral and bacterial infections, ...
Accelerated by the COVID-19 pandemic, research is now exploring vaccines capable not only of preventing infections, but also ...
ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...
Key market opportunities in the RNA Therapy Clinical Trials sector include an increase in chronic and rare diseases, advancements in delivery technologies like lipid nanoparticles, robust venture ...
A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...
This article explores how next-generation vaccines are expanding beyond infectious disease to target chronic conditions while ...
A biotech that lost federal funding Tuesday following Health Secretary Robert F. Kennedy Jr.’s edict that his agency’s pandemic preparedness division stop funding development of messenger RNA-based ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide. Multiple vaccine ...
Immunomic Therapeutics, Inc. ("ITI"), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results